Q-omics provides the consensus-scored GPR42 profile across patient tissues and cancer cell-line models. GPR42 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, GPR42 is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, GPR42 RNA expression shows 7,695 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight STAD, BRCA, and UVM as cancer lineages where GPR42 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR42 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR42 survival associations across molecular data types. GPR42 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR42 RNA expression–survival associations across cancer types. High GPR42 expression shows unfavorable associations in STAD, UVM, TGCT, BRCA, THYM and ACC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for GPR42 RNA expression.
This table summarizes GPR42 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for GPR42. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR42 shows lower tumor expression in BRCA, LUSC and BLCA and higher tumor expression in KIRC, HNSC and LIHC. The BRCA box plot shows higher GPR42 RNA expression in normal versus tumor tissue (log2 FC = −0.061, t-test p < 0.001).
This table shows molecular features associated with GPR42 in patient tissues and cancer cell lines. In patient samples, GPR42 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR42 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LIVER.
